Dipal Doshi - 26 Sep 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Signature
/s/ Jared Cohen, as Attorney-in-Fact
Issuer symbol
TRDA
Transactions as of
26 Sep 2022
Net transactions value
-$161,442
Form type
4
Filing time
28 Sep 2022, 17:12:50 UTC
Previous filing
23 Sep 2022
Next filing
24 Oct 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Sale $42,530 -2,795 -1.3% $15.22 212,627 26 Sep 2022 Direct F1, F2
transaction TRDA Common Stock Sale $4,695 -288 -0.14% $16.30 212,339 26 Sep 2022 Direct F1, F3
transaction TRDA Common Stock Sale $51,934 -3,453 -1.6% $15.04 208,886 27 Sep 2022 Direct F1, F4
transaction TRDA Common Stock Sale $15,286 -966 -0.46% $15.82 207,920 27 Sep 2022 Direct F1, F5
transaction TRDA Common Stock Sale $46,997 -3,085 -1.5% $15.23 204,835 28 Sep 2022 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.12 to $16.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.51 to $15.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.51 to $16.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.